Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Expert Ratings for Bausch Health Companies
03:08pm, Thursday, 01'st Sep 2022 Benzinga
Bausch Health Companies (NYSE:BHC) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
4
0
0
Where Bausch Health Companies Stands With Analysts
01:16pm, Thursday, 01'st Sep 2022 Benzinga
Analysts have provided the following ratings for Bausch Health Companies (NYSE:BHC) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
4
Why Nuwellis Surged Over 121%; Here Are 66 Biggest Movers From Yesterday
09:19am, Thursday, 01'st Sep 2022 Benzinga
Gainers
Nuwellis, Inc. (NASDAQ: NUWE) shares climbed 121.3% to close at $1.46 on Wednesday after the company announced new clinical data demonstrating 100% survival at 30 days following the use of ul
Why Express Is Trading Higher By Over 21%, Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
04:47pm, Wednesday, 31'st Aug 2022 Benzinga
Gainers
Nuwellis, Inc. (NASDAQ: NUWE) shares jumped 140% to $1.5894 after the company announced new clinical data demonstrating 100% survival at 30 days following the use of ultrafiltration in high-r
Snap, Meta Platforms, Pinterest And Some Other Big Stocks Moving Higher On Wednesday
02:54pm, Wednesday, 31'st Aug 2022 Benzinga
Barnes & Noble Education, Inc. (NYSE: BNED) gained 16.8% to $2.64 after reporting upbeat quarterly sales.
Bausch Health Companies Inc. (NYSE: BHC) gained 15.5% to $5.91.
ChargePoint Holdings, Inc. (
Why Is Bausch Health (BHC) Up 17% Today?
02:25pm, Wednesday, 31'st Aug 2022
In today's rather volatile session, investors looking for big movers do have their fair share to consider. Among the biggest gainers in today's market is Bausch Health (NYSE: BHC ).
Bausch (BHC) to Appeal Regarding Xifaxan Patent Decision
02:05pm, Monday, 15'th Aug 2022 Zacks Investment Research
Bausch (BHC) will appeal to the U.S. Court of Appeals for the Federal Circuit regarding the patent decision for one of its key drugs Xifaxan.
7 Stock Price Predictions That Are Actually Worth Listening To
06:10am, Friday, 12'th Aug 2022
Generally, Wall Street stock price predictions are hardly the best source of investing ideas that have the most upside. Investors should interpret stocks that analysts claim have the most upside caref
The Inverse Jim Cramer Strategy
07:58pm, Thursday, 11'th Aug 2022 Seeking Alpha
There is a clear and distinct trend throughout the history of stock investing slowly moving away from the professional money managers into the hands of the everyday man.
Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down
03:56pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
Bausch (BHC) Q2 Earnings & Sales Miss, View Cut, Stock Down
01:32pm, Wednesday, 10'th Aug 2022
Bausch (BHC) Q2 earnings and sales miss in the second quarter. The company cuts its annual guidance due to the uncertainties in the overall operating environment.
Why Bausch Health Stock Tumbled More Than 11% on Tuesday
08:42pm, Tuesday, 09'th Aug 2022 The Motley Fool
Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.
Why Bausch Health Stock Tumbled More Than 11% on Tuesday
04:42pm, Tuesday, 09'th Aug 2022
Investors are increasingly realizing the scope of the turnaround project CEO Thomas Appio has on his plate.
Bausch Health (BHC) Q2 Earnings and Revenues Miss Estimates
12:35pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Bausch (BHC) delivered earnings and revenue surprises of -38.20% and 3.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bausch Health Companies Inc. (BHC) CEO Thomas Appio on Q2 2022 Results - Earnings Call Transcript
12:15pm, Tuesday, 09'th Aug 2022
Bausch Health Companies Inc. (NYSE:BHC ) Q2 2022 Earnings Conference Call August 9, 2022 8:00 AM ET Company Participants Christina Cheng - Senior Vice President, Investor Relations Thomas Appio - Chie
